awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q39650689-5ED38BF0-DAC3-4DCD-8F05-1E78B1078DB3
Q39650689-5ED38BF0-DAC3-4DCD-8F05-1E78B1078DB3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39650689-5ED38BF0-DAC3-4DCD-8F05-1E78B1078DB3
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
P2860
Q39650689-5ED38BF0-DAC3-4DCD-8F05-1E78B1078DB3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39650689-5ED38BF0-DAC3-4DCD-8F05-1E78B1078DB3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
18c59e04d3c5180a93ab4a6620c9db96b3f0c838
P2860
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.